- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.04. | Journey Medical Corp - 8-K, Current Report | 2 | SEC Filings | ||
| 01.04. | Journey Medical appoints Ramsey Alloush as COO | 1 | Seeking Alpha | ||
| 01.04. | Journey Medical Corporation Appoints Ramsey Alloush as Chief Operating Officer | 65 | GlobeNewswire (Europe) | SCOTTSDALE, Ariz., April 01, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) ("Journey Medical" or the "Company"), a commercial-stage pharmaceutical company that primarily focuses... ► Artikel lesen | |
| 01.04. | Journey Medical appoints new COO amid growth phase | 2 | Investing.com | ||
| JOURNEY MEDICAL Aktie jetzt für 0€ handeln | |||||
| 26.03. | Journey Medical GAAP EPS of -$0.72 beats by $0.44, revenue of $56.13M misses by $0.59M | 4 | Seeking Alpha | ||
| 26.03. | Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights | 618 | GlobeNewswire (Europe) | FDA Approval of Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules) for Rosacea Emrosi Initial Distribution Ongoing; First Prescriptions Filled Total Revenues for the Full Year Ended... ► Artikel lesen | |
| 24.03. | Journey Medical Corporation Launches Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea | 3 | GlobeNewswire (USA) | ||
| 24.03. | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 19.03. | Journey Medical Corporation to Announce Year End 2024 Financial Results on March 26, 2025 | 3 | GlobeNewswire (USA) | ||
| 05.03. | FDA approves new rosacea treatment from Journey Medical | 2 | Investing.com | ||
| 04.03. | Journey Medical Corporation to Exhibit at the 2025 American Academy of Dermatology Annual Meeting in Orlando, Florida | 1 | GlobeNewswire (USA) | ||
| 20.02. | Journey Medical Corporation (DERM): A Bull Case Theory | 1 | Insider Monkey | ||
| 05.02. | Journey Medical Corp - 8-K, Current Report | - | SEC Filings | ||
| 24.01. | Minot Light Capital's Largest Performance Detractor in Q4: Journey Medical (DERM) | 2 | Insider Monkey | ||
| 13.11.24 | Journey Medical GAAP EPS of -$0.12 beats by $0.03, revenue of $14.63M beats by $0.24M | 1 | Seeking Alpha | ||
| 12.11.24 | Journey Medical Corporation Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights | 174 | GlobeNewswire (Europe) | U.S. FDA approved Emrosi (Minocycline Hydrochloride Extended Release Capsules, 40 mg) for the treatment of inflammatory lesions of rosacea in adults; launch expected in late Q1 or early Q2 of 2025... ► Artikel lesen | |
| 12.11.24 | Journey Medical Corp - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.24 | FDA approves Journey Medical's Emrosi to treat inflammatory lesions of rosacea | - | PMLiVE | ||
| 05.11.24 | FDA approves Journey Medical's rosacea treatment Emrosi | 1 | Pharmaceutical Technology | ||
| 04.11.24 | Journey Medical, with FDA nod, won't stop believing it can establish new rosacea standard of care | 3 | FiercePharma |
Seite:
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 20,015 | 0,00 % | Ihre wichtigsten Termine: Alle Blicke auf: Intel, Pepsico, Pfizer, Boeing, Nestle, Asos, Johnson & Johnson | © Foto: Intel CorporationGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:30... ► Artikel lesen | |
| GILEAD SCIENCES | 93,00 | -0,26 % | Interessante Einstiege finden - BioNTech, BioNxt Solutions, Gilead Sciences, Merck & Co. | Die aggressive Zollpolitik der US-Administration unter US-Präsident Trump hat zu Umschichtungsprozessen bei den Anlegern geführt. So zogen europäische ETF-Anleger über eine Milliarde Euro aus US-Aktien-ETFs... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 430,85 | -0,37 % | ToolGen Files Patent Infringement Lawsuit Against Vertex Pharmaceuticals in the United Kingdom | ToolGen commences legal action in UK court over Vertex's genome editing therapy, CASGEVY ®Seeks to expand licensing of its proprietary CRISPR RNP technologySEOUL, South Korea, April 21, 2025... ► Artikel lesen | |
| EYEPOINT PHARMACEUTICALS | 5,864 | +1,98 % | EyePoint Pharmaceuticals, Inc.: EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) | WATERTOWN, Mass., April 16, 2025 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a company committed to developing and commercializing therapeutics to help improve the lives of... ► Artikel lesen | |
| ASTRIA THERAPEUTICS | 4,200 | -8,30 % | Astria Therapeutics, Inc.: Astria Therapeutics beginnt Phase-3-Zulassungsstudie ALPHA-ORBIT zu Navenibart bei hereditärem Angioödem | -- Studie zum Nachweis der Wirksamkeit und Sicherheit der Verabreichung alle 3 und alle 6 Monate in einem 6-monatigen Behandlungszeitraum --
Astria Therapeutics, Inc. (Nasdaq: ATXS), ein biopharmazeutisches... ► Artikel lesen | |
| ROCKET LAB USA | 19,246 | +0,21 % | Rocket Lab Stock Is Shooting Higher Thursday: What's Fueling The Launch? | ||
| OPKO HEALTH | 1,210 | -5,94 % | OPKO HEALTH, INC. - 8-K, Current Report | ||
| LIGAND PHARMACEUTICALS | 92,00 | -3,66 % | Ligand, Channel Therapeutics Agree To Combine Pelthos, LNHC With CHRO Merger Sub | WASHINGTON (dpa-AFX) - Ligand Pharmaceuticals Inc. (LGND) Thursday announced a definitive merger agreement with Channel Therapeutics Corp. (CHRO) to combine Ligand's wholly owned subsidiaries... ► Artikel lesen | |
| JAZZ PHARMACEUTICALS | 95,12 | -0,71 % | Jazz Pharmaceuticals plc: Jazz Pharmaceuticals to Report First Quarter Financial Results on May 6, 2025 | DUBLIN, April 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 first quarter financial results on Tuesday, May 6, 2025, after... ► Artikel lesen | |
| ROYALTY PHARMA | 27,970 | -0,57 % | Royalty Pharma declares $0.22 dividend | ||
| CATALYST PHARMACEUTICALS | 20,530 | +0,74 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025 | ||
| TG THERAPEUTICS | 35,265 | 0,00 % | MaxCyte, Inc: MaxCyte Signs Strategic Platform License with TG Therapeutics to Advance its Autoimmune Cell Therapeutics Programs | ROCKVILLE, Md., Feb. 12, 2025 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery... ► Artikel lesen | |
| CATALENT | 59,93 | 0,00 % | Silexion Therapeutics Stock Surges 52% On Catalent Collaboration For Cancer Therapy | ||
| CORBUS PHARMACEUTICALS | 7,150 | -2,72 % | Corbus Pharmaceuticals Holdings, Inc.: Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity | CB1 inverse agonism is a clinically validated mechanism to induce weight loss CRB-913 is markedly more peripherally restricted compared to monlunabant and rimonabantSAD/MAD Phase 1 trial scheduled... ► Artikel lesen | |
| TALPHERA | 0,444 | +6,99 % | Talphera, Inc.: Talphera Announces Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update | The U.S. Food and Drug Administration (FDA) agreed to reduce the number of patients in the NEPHRO CRRT study from 166 to 70
Talphera expects the registrational NEPHRO... ► Artikel lesen |
Das Unternehmen JOURNEY MEDICAL CORPORATION kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 7,530 Euro und damit +0,40 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu JOURNEY MEDICAL CORPORATION finden Sie auf Wallstreet Online.
